Daniel P. Petrylak, MD, discusses the recent FDA approval of the checkpoint inhibitor pembrolizumab for treating cystectomy-ineligible (or those who have refused cystectomy) non-muscle invasive bladder cancer patients who have also failed BCG. He details the prior lack of available treatment for this disease, explains the function of the drug as a checkpoint inhibitor, and describes the study that led to the drug’s approval.
Read More
E. David Crawford, MD, interviews Daniel P. Petrylak, MD, about a Phase 1b trial of cisplatin-ineligible bladder cancer patients given a combination of pembrolizumab and enfortumab vedotin that resulted in a 71% response rate. Dr. Petrylak details what makes a patient cisplatin-ineligible, discusses the partial and complete responses to the drug combination, and lays out future plans to study the efficacy of this therapy in the treatment of urothelial cancer.
Read More
Daniel P. Petrylak, MD, analyzes the current status of immunotherapy for prostate cancer, reviewing available options, emerging combination therapies, and immunotherapy clinical trials. He also emphasizes the impact of PD-L1 expression, microsatellite instability, and other mutations in prostate cancer on patient responses to immunotherapy.
Read More
Daniel P. Petrylak, MD, argues the advantages of using neoadjuvant chemotherapy prior to cystectomy to treat patients with muscle invasive bladder cancer (MIBC). He reviews evidence including the SWOG 87-10 trial and a meta-analysis to support this stance.
Read More
Daniel P. Petrylak, MD, provides an overview of immunotherapy treatment options for non-muscle invasive bladder cancer (NMIBC) including BCG, intravesical therapies, and checkpoint inhibitors. He also discusses clinical trials investigating alternative immunotherapy options for NMIBC other than BCG.
Read More